Ruiting Wen
Department of Pharmacy, Peking University People’s Hospital
Research Areas
Clinical Pharmacy
Neuropsychopharmacology
Education
Wuhan University, B.M. (Clinical Medicine), 2002-2007
Huazhong University of Science and Technology, B.A. (English), 2005-2007 Peking University Health Science Center, Ph.D. (Neuropsychopharmacology), 2007-2012
Positions
Department of Pharmacy, Peking University People’s Hospital, Pharmacist-in-charge 2012-2017, Associate Professor of Pharmacy 2017- West Virginia University Health Science Center, Visiting Scholar, 2017.03-2017.06
Research Interests
Our research directions involve both clinical pharmacy and basic neuroscience investigations. For clinical aspects, we focus on the pharmaceutical care of critical ill patients to improve the availability of individualized treatment. In basic neuroscience researches, we mainly explore the modulatory role of phosphodiesterase-4 (PDE4) and its subtypes (PDE4A, 4B, 4D) in alcohol use disorders. We also investigate the underlying mechanisms of alcohol-related disorders and the signal pathways by which PDE4s may interfere with these disorders.
Grants and fundings
1. National Natural Foundation of China (81503050) PI RMB 222,000
2. Research and Development Foundation for Scholar Exchange Program of Peking University People’s Hospital (RMD2016-05) PI RMB 50,000
Publications
Books Chapters (* Co-corresponding author)
1. Wen RT, Liang JH*, Zhang HT*. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence. Advances in Neurobiology 17. Phosphodiesterases: CNS Functions and Diseases. Springer. 2017; 17:413-444.
Journal Articles (* Co-corresponding author; # Co-first author)
1. Wen RT#, Zhang FF#, Zhang HT. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder. Psychopharmacology (Berl) . 2018; 235(6): 1793-1805.
2. Gong MF#, Wen RT#, Xu Y#, Pan JC, Fei N, Zhou YM, Xu JP*, Liang JH*, Zhang HT*. Attenuation of ethanol abstinence-induced anxiety and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents. Psychopharmacology (Berl) . 2017; 234(20): 3143-3151.
3. Huang L, Li Q, Wen RT, Yu ZY, Li N, Ma LP, Feng WY. Rho-kinase inhibitor prevents acute injury against transient focal cerebral ischemia by enhancing the expression and function of GABA receptors in rats. Eur J Pharmacol. 2017; 797: 134-142.
4. Wen RT, Feng WY, Liang JH*, Zhang HT*. Role of Phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence. Curr Pharm Des , 2015; 21(3): 355-364.
5. Qin WJ#, Wang YT#, Zhang M, Wen RT, Liu Q, Li YL, Chen F, Lawrence AJ, Liang JH. Molecular chaperone heat shock protein 70 participates in the labile phase of the development of behavioural sensitization induced by a single morphine exposure in mice. Int J Neuropsychopharmacol , 2013, 16(3): 647-659.
6. Zhang M, Jing L, Liu Q, Wen RT, Li JX, Li YL, Gong Q, Liang JH. Tramadol induces conditioned place preference in rats: Interactions with morphine and buprenorphine. Neurosci Lett , 2012, 520(1): 87-91.
7. Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, Zhang HT*, Liang JH*. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. Alcohol Clin Exp Res , 2012, 36(12): 2157-2167.